Hepatorenal Syndrome: Signs, Symptoms, and Diagnosis

 Hepatorenal Syndrome (HRS) generally develops in patients with advanced liver disease and may present with gradual or rapidly progressive deterioration in renal function.

The clinical manifestations are related to both hepatic decompensation and impaired kidney function.

 

4.1 Clinical signs and symptoms

1. Oliguria

Oliguria is a common manifestation of significant renal dysfunction and refers to reduced urine output. It may occur because of decreased renal perfusion and reduced GFR.

However, oliguria is not essential for diagnosing HRS-AKI, as serum creatinine changes may precede substantial reductions in urine output.

2. Ascites

Ascites is the accumulation of fluid within the peritoneal cavity. It results from portal hypertension, sodium retention, and increased fluid movement into the abdominal cavity.

Patients with HRS frequently have severe or refractory ascites.

3. Peripheral edema

Fluid retention may cause bilateral lower-limb edema, particularly in patients with advanced hepatic dysfunction and hypoalbuminemia.

4. Fatigue and generalized weakness

Patients may experience persistent fatigue, reduced physical activity, and generalized weakness due to hepatic dysfunction, renal impairment, electrolyte disturbances, and systemic inflammation.

5. Jaundice

Jaundice occurs because of impaired hepatic bilirubin metabolism and excretion. It is a common feature of advanced liver disease but is not specific to HRS.

6. Hepatic encephalopathy

Patients may develop confusion, altered consciousness, disorientation, and, in severe cases, coma due to impaired hepatic detoxification and accumulation of neurotoxic substances.

7. Fluid overload and respiratory symptoms

Severe sodium and water retention may cause pulmonary congestion, pleural effusions, and respiratory difficulty, particularly when renal dysfunction is advanced.

4.2 Laboratory findings

Laboratory investigations play an important role in evaluating renal dysfunction, identifying precipitating conditions, and excluding alternative causes.

Investigation    Typical findings or significance

Serum creatinine    Increased

Blood urea nitrogen                Frequently increased

Estimated GFR        Reduced, although creatinine-based estimates may be inaccurate in cirrhosis

Serum sodium         May be reduced due to dilutional hyponatremia

Serum potassium    May be increased, particularly in advanced renal dysfunction

Serum albumin       Frequently reduced due to impaired hepatic synthesis and other factors

Serum bilirubin       Often elevated due to hepatic dysfunction

Urinalysis                 May be relatively bland, although abnormalities do not exclude HRS

Urine sodium           Frequently low, but not reliable as a standalone diagnostic test

Urine osmolality      May be relatively high because of ADH-mediated water retention

It is important to recognize that serum creatinine may underestimate the severity of renal dysfunction in patients with cirrhosis because of reduced muscle mass, impaired hepatic creatine synthesis, and altered creatinine production.

4.3 Diagnostic criteria for HRS-AKI

The 2024 joint consensus recommendations of the Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) provide updated diagnostic criteria for HRS-AKI.

The diagnosis requires the following:

1. Underlying cirrhosis with ascites.

2. Evidence of acute kidney injury, defined by one or both of the following:

• Increase in serum creatinine of at least 0.3 mg/dL (26.5 µmol/L) within 48 hours.
• Increase in serum creatinine of at least 50% from baseline, known or presumed to have occurred within the preceding seven days.

Alternatively, urine output of 0.5 mL/kg/hour or less for at least six hours may establish AKI.

3. No improvement in serum creatinine and/or urine output within 24 hours following adequate volume resuscitation, when clinically indicated.

4. Absence of strong evidence for an alternative explanation as the primary cause of AKI.

An important change in the 2024 consensus is that a mandatory 48-hour albumin administration period is no longer required before diagnosing HRS-AKI. This helps avoid unnecessary delays in treatment and prevents inappropriate albumin administration in patients who are already volume overloaded.

4.4 Classification of HRS

Contemporary terminology classifies HRS according to the duration and nature of kidney dysfunction.

Classification    Description

HRS-AKI               Hepatorenal syndrome associated with acute kidney injury

HRS-AKD             Hepatorenal syndrome associated with acute kidney disease lasting less than 90 days

HRS-CKD             Hepatorenal syndrome associated with chronic kidney disease lasting more than 90 days

The previous type 1 and type 2 classifications are largely historical and have been replaced by this newer framework.

4.5 Differential diagnosis

HRS must be differentiated from other causes of renal dysfunction in patients with liver disease.

Important differential diagnoses include:

• Acute tubular injury or necrosis.
• Pre-renal AKI due to dehydration or hemorrhage.
• Sepsis-associated AKI.
• Drug-induced nephrotoxicity.
• Glomerulonephritis.
• Acute interstitial nephritis.
• Urinary tract obstruction.
• Pre-existing chronic kidney disease.

Urinalysis, urine microscopy, renal ultrasonography, clinical assessment, and selected kidney injury biomarkers may help distinguish these conditions.

However, HRS can coexist with tubular injury or chronic kidney disease; therefore, the presence of some structural abnormalities does not automatically exclude HRS.

4.6 Additional investigations

The following investigations may be useful:

• Complete blood count to identify infection, anemia, and thrombocytopenia.
• Liver function tests to assess hepatic impairment.
• Coagulation profile, particularly prothrombin time and INR.
• Blood and urine cultures when infection is suspected.
• Diagnostic paracentesis to evaluate for spontaneous bacterial peritonitis.
• Renal ultrasonography to exclude obstruction and assess renal anatomy.
• Electrocardiography when electrolyte disturbances are suspected.
• Chest radiography and oxygenation assessment when fluid overload or respiratory complications are present.

Clinical importance: Early identification of HRS-AKI is particularly important because treatment response is generally more favorable when therapy is initiated before severe and prolonged renal impairment develops.

Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

                                                                    

CONTINUE READING

 Hepatorenal Syndrome: Management

 

Hepatorenal Syndrome: Causes and Risk Factors

HRS generally develops in patients with severe hepatic dysfunction and circulatory disturbances. Although advanced cirrhosis is the most common underlying condition, several other hepatic disorders and clinical complications may contribute to its development.

  3. Causes and Risk Factors of Hepatorenal Syndrome

HRS generally develops in patients with severe hepatic dysfunction and circulatory disturbances. Although advanced cirrhosis is the most common underlying condition, several other hepatic disorders and clinical complications may contribute to its development.

3.1 Cirrhosis

Cirrhosis is the leading cause of HRS. It is characterized by progressive hepatic fibrosis, regenerative nodule formation, and distortion of the normal hepatic vascular architecture.

These changes increase intrahepatic vascular resistance and produce portal hypertension.

As cirrhosis progresses, patients develop complications such as:

• Ascites.
• Portal hypertension.
• Esophageal and gastric varices.
• Hepatic encephalopathy.
• Spontaneous bacterial peritonitis.
• Coagulopathy.
• Progressive hepatic dysfunction.

The presence of ascites, particularly refractory ascites, indicates advanced circulatory dysfunction and increases the likelihood of developing HRS.

3.2 Acute liver failure

Acute liver failure is characterized by rapid deterioration of hepatic function in a patient without pre-existing cirrhosis, generally accompanied by coagulopathy and hepatic encephalopathy.

Although HRS is classically associated with cirrhosis and ascites, severe acute liver failure can also cause renal dysfunction through systemic inflammation, hemodynamic instability, endothelial dysfunction, and impaired renal perfusion.

It is important to distinguish HRS-like renal dysfunction in acute liver failure from formally defined HRS-AKI, whose contemporary diagnostic criteria require cirrhosis with ascites.

3.3 Viral hepatitis

Chronic viral hepatitis, particularly hepatitis B and hepatitis C, can lead to progressive hepatic inflammation, fibrosis, and cirrhosis.

Patients with advanced viral hepatitis-related cirrhosis are at increased risk of developing HRS, especially when complicated by portal hypertension, ascites, or infection.

3.4 Alcohol-associated liver disease

Long-term excessive alcohol consumption can cause alcoholic hepatitis, hepatic steatosis, fibrosis, and cirrhosis.

Severe alcohol-associated hepatitis may produce systemic inflammation and circulatory disturbances, increasing susceptibility to acute kidney injury and HRS.

3.5 Metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), particularly its progressive inflammatory form, can cause advanced fibrosis and cirrhosis.

Patients with decompensated MASLD-related cirrhosis may develop HRS through the same portal hypertensive and circulatory mechanisms observed in other forms of cirrhosis.

3.6 Other contributing conditions

Other liver diseases that may eventually result in advanced cirrhosis and predispose patients to HRS include:

• Autoimmune hepatitis.
• Primary biliary cholangitis.
• Primary sclerosing cholangitis.
• Hemochromatosis.
• Wilson disease.
• Alpha-1 antitrypsin deficiency.
• Vascular liver disorders, including Budd–Chiari syndrome.

3.7 Precipitating factors

·         Several clinical events can trigger HRS in patients with advanced liver disease.

·         A. Spontaneous bacterial peritonitis

·         SBP is a major precipitating factor. Infection triggers systemic inflammation and worsens circulatory dysfunction, potentially resulting in acute renal impairment.

·         B. Gastrointestinal bleeding

·         Bleeding from esophageal varices or other gastrointestinal sources causes intravascular volume depletion and reduced renal perfusion.

·         C. Excessive diuretic therapy

·         Overuse of diuretics can result in intravascular volume depletion, electrolyte disturbances, and worsening renal perfusion.

·         D. Large-volume paracentesis without adequate albumin replacement

·         Removal of large amounts of ascitic fluid without appropriate albumin replacement can produce post-paracentesis circulatory dysfunction and increase the risk of renal impairment.

·         E. Severe dehydration

·         Vomiting, diarrhea, poor oral intake, and inadequate fluid replacement may reduce circulating blood volume and precipitate AKI.

·         F. Nephrotoxic medications

·         Non-steroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, and other nephrotoxic agents can aggravate renal dysfunction in patients with cirrhosis.

·         G. Severe hepatic decompensation

·         Acute-on-chronic liver failure (ACLF), severe alcoholic hepatitis, and advanced portal hypertension are associated with increased systemic inflammation and circulatory instability.

3.8 Major risk factors

Risk factor                          Mechanism contributing to HRS

Advanced cirrhosis                       Severe portal hypertension and circulatory dysfunction

Refractory ascites                          Persistent sodium retention and arterial underfilling

Spontaneous bacterial peritonitis Systemic inflammation and hemodynamic deterioration

Gastrointestinal bleeding             Reduced circulating blood volume

Hyponatremia                                Marker of advanced circulatory dysfunction

Excessive diuretic use                 Intravascular volume depletion

Large-volume paracentesis         Post-paracentesis circulatory dysfunction

Nephrotoxic medications             Additional renal injury

Acute-on-chronic liver failure     severe systemic inflammation and organ dysfunction

Early identification and correction of these precipitating factors are essential to prevent progression to severe renal dysfunction.

 Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

 

                                                                

 

Continue Reading

 Hepatorenal Syndrome: Signs, Symptoms, and Diagnosis

 

Hepatorenal Syndrome (HRS): Pathophysiology

Abstract

Hepatorenal syndrome (HRS) is a serious and potentially life-threatening complication of advanced liver disease, characterized by impaired renal function resulting from complex circulatory, hemodynamic, inflammatory, and neurohormonal alterations associated with hepatic dysfunction. It is most commonly encountered in patients with advanced cirrhosis and ascites, although it may also occur in other severe hepatic conditions. HRS represents a functional form of kidney dysfunction in which profound renal vasoconstriction and reduced effective arterial blood volume play central roles. However, contemporary evidence recognizes that structural kidney injury and systemic inflammation may coexist with the functional renal impairment.

HRS is associated with substantial morbidity and mortality, making early recognition, accurate diagnosis, and prompt treatment essential. Recent advances have improved the understanding and classification of HRS, particularly through the distinction between acute kidney injury (HRS-AKI) and non-AKI phenotypes (HRS-NAKI). Management involves identifying and treating precipitating factors, optimizing circulatory function, administering vasoconstrictor therapy with albumin, managing complications, and evaluating patients for liver transplantation. Terlipressin is generally the preferred pharmacological treatment where available, while norepinephrine and midodrine combined with octreotide are alternative options in appropriate clinical settings.

  1. Introduction

Hepatorenal syndrome (HRS) is a potentially reversible form of kidney dysfunction that develops in patients with advanced liver disease, particularly those with decompensated cirrhosis and ascites. It results from profound disturbances in systemic and renal circulation, primarily caused by portal hypertension, splanchnic arterial vasodilation, reduced effective arterial blood volume, and compensatory activation of several vasoconstrictor systems.

Although HRS was traditionally considered a purely functional renal disorder without significant structural abnormalities, contemporary research suggests that its pathogenesis is more complex. Systemic inflammation, bacterial translocation, endothelial dysfunction, and associated tubular injury may contribute to renal impairment. Consequently, HRS is now understood as a clinical syndrome that can involve both functional circulatory disturbances and structural kidney injury.

HRS is one of the most serious complications of advanced cirrhosis because it is associated with rapid deterioration in renal function, electrolyte disturbances, fluid overload, and increased mortality. It frequently develops in patients who already have complications such as refractory ascites, spontaneous bacterial peritonitis (SBP), gastrointestinal bleeding, or severe hepatic decompensation.

The clinical significance of HRS lies in its association with poor short-term survival if left untreated. Nevertheless, early diagnosis and appropriate intervention can improve renal function and provide an opportunity for definitive treatment through liver transplantation.

Historically, HRS was classified into type 1 and type 2:

• Type 1 HRS: Characterized by rapidly progressive renal dysfunction, often associated with acute deterioration in liver function or a precipitating event.
• Type 2 HRS: Characterized by a more gradual decline in renal function, frequently associated with refractory ascites.

This classification has largely been replaced by a phenotype-based approach that distinguishes HRS associated with acute kidney injury from HRS without acute kidney injury. The contemporary terminology includes HRS-AKI, HRS-AKD, and HRS-CKD, reflecting the duration and progression of renal dysfunction.

This updated classification is important because it facilitates earlier diagnosis, improves clinical decision-making, and allows treatment to be initiated before severe renal impairment develops.

2. Pathophysiology of Hepatorenal Syndrome

The pathophysiology of HRS is complex and involves interactions between portal hypertension, systemic circulatory dysfunction, renal hemodynamic alterations, neurohormonal activation, and systemic inflammation. The central mechanism is a reduction in effective arterial blood volume that leads to compensatory renal vasoconstriction and decreased renal perfusion.

2.1 Portal hypertension and splanchnic vasodilation

Portal hypertension is one of the primary initiating factors in the development of HRS. In advanced cirrhosis, increased intrahepatic vascular resistance results from hepatic fibrosis, regenerative nodules, and alterations in the hepatic microcirculation.

As portal pressure increases, several vasodilatory substances are released within the splanchnic circulation. Nitric oxide (NO) is particularly important, although other mediators, including carbon monoxide, prostacyclin, and endocannabinoids, also contribute.

These substances cause marked dilation of the splanchnic arterial circulation, resulting in pooling of blood within the abdominal vascular compartment.

Although total blood volume may be normal or increased, the effective arterial blood volume decreases. This phenomenon is known as arterial underfilling and represents a major stimulus for compensatory neurohormonal activation.

2.2 Activation of the renin–angiotensin–aldosterone system (RAAS)

Reduced effective arterial blood volume stimulates the kidneys to activate the renin–angiotensin–aldosterone system.

The juxtaglomerular apparatus releases renin, which converts angiotensinogen into angiotensin I. Angiotensin-converting enzyme subsequently converts angiotensin I into angiotensin II.

Angiotensin II produces systemic and renal vasoconstriction and stimulates aldosterone secretion from the adrenal cortex.

Aldosterone increases sodium reabsorption in the distal nephron, resulting in sodium and water retention. Although these mechanisms initially help maintain arterial pressure, persistent activation contributes to:

• Renal vasoconstriction.
• Reduced renal blood flow.
• Decreased glomerular filtration rate (GFR).
• Sodium and water retention.
• Development or worsening of ascites and peripheral edema.

2.3 Activation of the sympathetic nervous system

Reduced arterial filling also activates the sympathetic nervous system through arterial baroreceptors.

Increased sympathetic activity leads to the release of norepinephrine and other catecholamines. These substances produce vasoconstriction, particularly in the renal circulation.

Persistent sympathetic stimulation causes a reduction in renal cortical perfusion and contributes to progressive impairment of kidney function.

2.4 Increased antidiuretic hormone secretion

The non-osmotic release of antidiuretic hormone (ADH), also known as vasopressin, occurs in response to reduced effective arterial blood volume.

ADH acts on V2 receptors in the collecting ducts of the kidneys, increasing water reabsorption through aquaporin-2 channels.

Excessive water retention contributes to dilutional hyponatremia, which is frequently observed in patients with advanced cirrhosis and HRS.

2.5 Renal vasoconstriction and reduced glomerular filtration

The combined effects of RAAS activation, sympathetic stimulation, and other vasoactive mediators result in intense renal vasoconstriction.

This reduces renal blood flow and glomerular filtration pressure, leading to a decline in GFR.

Initially, the kidneys may retain their structural integrity, and renal dysfunction may improve following restoration of effective arterial circulation. However, prolonged hypoperfusion, systemic inflammation, and associated cellular injury can produce tubular damage.

Consequently, HRS should not be regarded as an exclusively functional disorder. Functional renal circulatory abnormalities and structural kidney injury may coexist.

2.6 Role of systemic inflammation and bacterial translocation

Systemic inflammation is increasingly recognized as an important contributor to HRS.

Advanced cirrhosis is associated with increased intestinal permeability, altered gut microbiota, and bacterial translocation from the intestinal lumen into the systemic circulation.

Bacterial products, including lipopolysaccharides, stimulate the release of inflammatory cytokines such as:

• Tumor necrosis factor-alpha (TNF-α).
• Interleukin-6 (IL-6).
• Interleukin-1 beta (IL-1β).

These inflammatory mediators contribute to endothelial dysfunction, circulatory instability, oxidative stress, and renal cellular injury.

Infections such as spontaneous bacterial peritonitis can intensify systemic inflammation and precipitate acute renal deterioration.

2.7 Role of vasoactive substances

Several vasoactive substances contribute to the hemodynamic abnormalities associated with HRS.

Vasoactive substance       Main effect

Nitric oxide    Produces splanchnic vasodilation

Angiotensin II           Causes renal and systemic vasoconstriction

Norepinephrine        Increases sympathetic-mediated vasoconstriction

Endothelin-1 Promotes renal vasoconstriction

Vasopressin  Increases water reabsorption and contributes to water retention

Prostacyclin  Contributes to systemic and splanchnic vasodilation

Endocannabinoids  Contribute to vascular relaxation

The imbalance between excessive splanchnic vasodilation and compensatory renal vasoconstriction is fundamental to the development of HRS.

2.8 Summary of the pathophysiological sequence

The development of HRS can be summarized as follows:

1. Advanced liver disease causes increased intrahepatic vascular resistance.
2. Portal hypertension develops.
3. Splanchnic vasodilation occurs due to increased production of vasodilatory mediators.
4. Effective arterial blood volume decreases.
5. RAAS, sympathetic nervous system, and ADH are activated.
6. Renal vasoconstriction and sodium and water retention increase.
7. Renal blood flow and GFR decrease.
8. Progressive renal dysfunction develops, resulting in HRS.

 Medical Disclaimer: The information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions or starting, changing, or stopping any treatment. Do not ignore or delay seeking medical advice based on information published on this blog.

                                                             

 Further Reading

Hepatorenal Syndrome:Causes and Risk Factors